Effects of Ranolazine on Vasomotor Responses of Rat Aortic Rings

Archives of Medical Research

Volumn 44, Issue 1, 2013, Pages 8-12

  Paredes Carbajal, Ma Cristina ^a   Monsalvo, Ivan ^b   Hernández Díaz, Carlos ^a   Regla, Ignacio ^b   Demare, Patricia ^b   Mascher, Dieter ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Endothelium; Nitric oxide; Smooth muscle; Stable angina; Vasodilation

Indexed keywords

INDOMETACIN; N(G) NITROARGININE METHYL ESTER; PHENYLEPHRINE; PROSTAGLANDIN SYNTHASE; RANOLAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; MALE; NONHUMAN; RAT; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION; VASOMOTOR REFLEX;

ACETANILIDES; ANGINA, STABLE; ANIMALS; AORTA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; INDOMETHACIN; MALE; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; PIPERAZINES; RATS; RATS, WISTAR; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 84873197571     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.11.002     Document Type: Article

References (19)

1. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. JAMA 2004, 291:309-316.
2. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004, 43:1375-1382.
3. Clarke B., Spedding M., Patmore L., et al. Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol 1993, 109:748-750.
4. Clarke B., Wyatt K.M., McCormack J.G. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 1996, 28:341-350.
5. Rousseau M.F., Pouleur H., Cocco G., et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005, 95:311-316.
6. Stone P.H., Chaitman B.R., Stocke K., et al. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol 2010, 56:934-942.
7. Reffelmann T., Kloner R.A. Ranolazine: an anti-anginal drug with further therapeutic potential. Exp Rev Cardiovasc Ther 2010, 8:319-329.
8. Belardinelli L., Shryock J.C., Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006, 92:iv6-iv14.
9. Antzelevitch C., Belardinelli L., Zygmunt A.C., et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004, 110:904-910.
10. Na in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2004, 44:192-199.
11. Na and cause ventricular diastolic dysfunction. Am Soc Pharmacol ExpTherap 2009, 330:550-557.
12. Lètienne R., Viè B., Puech A., et al. Evidence that ranolazine behaves as a B1 and B2-adrenoceptor antagonist in the rat cardiovascular system. Naunyn-Schmiedeberg's Arch Pharmacol 2001, 363:464-471.
13. Zhao G., Walsh E., Shryock J., et al. Anti-adrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol 2011, 57:639-647.
14. Nieminen T., Caio A.M., Tavares C.A.M., et al. Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model. Circ Cardiovasc Interv 2011, 4:481-487.
15. NOM-062-ZOO. NORMA Oficial Mexicana NOM-062-ZOO-1999, Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio.
16. Paredes-Carbajal M.C., Juárez-Oropeza M.A., Ortiz Mendoza C.M., et al. Effects of acute and chronic estrogenic treatment on vasomotor responses of aortic rings from ovariectomized rats. Life Sci 1995, 57:473-486.
17. Paredes-Carbajal M.C., Torres-Durán P.V., Díaz-Zagoya J.C., et al. Effects of dietary Spirulina maxima on endothelium dependent vasomotor responses of rat aortic rings. Life Sci 1997, 61:PL211-PL219.
18. Riise-Moen A., Karstad R., Anthonsen T. Chemo-enzymatic synthesis of both enantiomers of the anti-anginal drug ranolazine. Biocatal Biotrans 2005, 23:45-51.
19. Deng C.Y., Kuang S.J., Rao F., et al. Effect of ranolazine on rat intrarenal arteries in vitro. Eur J Pharmacol 2012, 683:211-216.